SenoRx Announces 510(k) Clearance for Its Breast Biopsy Ultrasound System

ALISO VIEJO, Calif., Oct. 17, 2007 (PRIME NEWSWIRE) -- SenoRx, Inc. (NasdaqGM:SENO - News) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its SenoSonix(tm) System, an integration of its EnCor(r) breast biopsy system with a state-of-the-art ultrasound imaging system. The device incorporates SenoRx's proprietary EnCor vacuum-assisted biopsy technologies with an ultrasound system developed and sold by Ultrasonix Medical Corporation of Canada. SenoRx and Ultrasonix have enjoyed a close working relationship, jointly developing the technology that facilitates the integration of the two products. The

Ultrasonix launched its innovative Sonix series of Smart Ultrasound systems in 2005 and has placed over 1,000 systems worldwide. Launching its flagship EnCor system in November 2005, SenoRx currently has an installed base of more than 400 of its breast biopsy systems in the United States and Canada.

pres release